Outcomes Summary. February 3-6, 2016 Keystone, Colorado

Similar documents
OUTCOMES SUMMARY REPORT

OUTCOMES SUMMARY REPORT

Case-Compare Impact Report

Final Outcomes Report 07/23/18

CME/CE POSTTEST CME/CE QUESTIONS

Actual Reach: 28 junior faculty/fellows; 9 expert faculty

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

Clinical Practice Guideline: Asthma

Are you confident in your diagnosis of asthma? Three case histories to challenge you

News on Evidence-Based Care Fourth Quarter 2013 Volume 5 Issue 4

NATIONAL ASSOCIATION FOR CONTINUING EDUCATION

ASTHMA CARE FOR CHILDREN BASKET OF CARE SUBCOMMITTEE Report to: Minnesota Department of Health. June 22, 2009

The Role of Allergy Testing to Achieve Personalized Treatment Goals for Allergic Rhinitis and Asthma

Current Approaches to Asthma & COPD

CME/CE QUIZ CME/CE QUESTIONS

An Insight into Allergy and Allergen Immunotherapy Co-morbidities of allergic disease

SCREENING AND PREVENTION

Minimum Competencies for Asthma Care in Schools: School Nurse

In 2002, it was reported that 72 of 1000

NATIONAL ASSOCIATION FOR CONTINUING EDUCATION

Clinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy

Drug Prior Authorization Guideline NUCALA (mepolizumab)

COPD: Applying New Guidelines to Optimizing Evaluation and Treatment

Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ

TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS

XOLAIR (omalizumab) Prior Authorization

2017 Chronic Respiratory. Program Evaluation. Our mission is to improve the health and quality of life of our members

How to distinguish between uncontrolled and severe asthma

Asthma COPD Overlap (ACO)

Activity Evaluation Summary

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum

Chronic obstructive pulmonary disease

Enhancing Patient Care

2012 Chronic Respiratory. Program Evaluation. Our mission is to improve the health and quality of life of our members

Alpha One Anti-Trypsin Deficiency: Challenges in Diagnosis and Treatment Final Outcome Report

Somkiat Wongtim Professor of Medicine Division of Respiratory Disease and Critical Care Chulalongkorn University

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton

Getting With The Guideline: Managing Pediatric ADHD in Your. Primary Care Practice

National COPD Audit Programme

Uncontrolled Moderate-to-Severe-Asthma: Latest Data from the Floor of CHEST 2018

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.

National Learning Objectives for Asthma Educators

Identifying and Managing Patients with Sarcoidosis Final Outcome Report

Project 3dii: Expansion of the Home Environmental Asthma Management Program

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

Public Dissemination

Asthma Tutorial. Trainer MRW. Consider the two scenarios, make an attempt at the questions, what guidance have you used?

This is a cross-sectional analysis of the National Health and Nutrition Examination

A preliminary assessment of nurses asthma education needs and the effect of a training. programme in an urban tertiary healthcare facility.

Improving Asthma Care: An Update for Managed Care

Global Initiative for Asthma (GINA) What s new in GINA 2016?

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

National Asthma Educator Certification Board Detailed Content Outline

Asthma. UVM. University of Vermont. Alicia Jacobs MD Fletcher Allen Health Care and the University of Vermont

Advances in the Multidisciplinary Management of Hepatocellular Carcinoma: Strategies for Incorporating Emerging Immunotherapy Treatment Options

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

Pathology of Asthma Epidemiology

Difficult Asthma Assessment: A systematic approach

COPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer

Using Pay-for-Performance to Improve COPD Care MHC64474 SV64474

Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD

Investigating Immunotherapies for Peanut Allergy Management

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

Provider Respiratory Inservice

CARE OF THE ADULT COPD PATIENT

Virginia Pharmacists Association 2019 Midyear Conference Hotel Roanoke February 16-17, 2019

Emerging Challenges in Primary Care: 2017

2. Does the patient have chronic urticaria? Y N

Treating Tardive Dyskinesia: Clinical Challenges and Patient Perspectives

Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007

Asthma: diagnosis and monitoring

Faculty. Faculty Disclosure

Making the Connection

Diagnosis, Treatment and Management of Asthma

Disclosure Statement. Epidemiological Data

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Making the Connection

LINEE GUIDA DELL ASMA: UP TO DATE

CONNECTION. Pulmonary Hypertension. National Jewish Health Accurate Diagnosis and Treatment from Right-Heart Experts.

Current Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012

Synergy Respiratory Care Dr. Lyle Melenka

INTERNAL MEDICINE FOR PRIMARY CARE: CARDIOLOGY/INFECTIOUS DISEASE/NEUROLOGY/PULMONARY

Asthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None

THE COPD-ASTHMA OVERLAP SYNDROME

Asthma ASTHMA. Current Strategies for Asthma and COPD

+ Asthma and Athletics

CARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE. Asheville, North Carolina The Omni Grove Park Inn May 18 20, 2018

The Arthur C. Nielsen, Jr. Vascular Symposium: A Clinical Update on Vascular Medicine and Surgery

September 16, :15 am 3:30 pm Prentice Women s Hospital 250 E. Superior St. Third Floor, Conference Room L South Chicago, Illinois 60611

Roflumilast (Daxas) for chronic obstructive pulmonary disease

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable

Making the Connection Between Patients and Providers

INITIATING A COPD CLINIC: PROTOCOL & ASSESSMENT

PATIENT-IMPACT SCORECARD

COPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute

Global Initiative for Asthma (GINA) What s new in GINA 2017?

Transcription:

Outcomes Summary February 3-6, 2016 Keystone, Colorado

Executive Summary Activity Details Background: The National Jewish Health Annual The Pulmonary and Allergy Update highlights insights and recent advances in pulmonary medicine, asthma, allergy and immunology, presented by faculty from the leading respiratory hospital in the nation. Participants have the opportunity to network with colleagues and nationally recognized experts, and learn the latest updates on management and treatment options for patients. Workshops and small-group sessions provide great opportunities to discuss key issues and interesting cases with colleagues and National Jewish Health faculty. Target Audience: Allergists, Pulmonologists, Primary Care and Internal Medicine Physicians, Pediatricians, Physician Assistants, Advanced Practice Nurses, Registered Nurses and others working with adults and children with allergic and pulmonary disease.

Executive Summary Activity Details Method of Learning: The 38 th Annual Pulmonary and Allergy Update incorporated live presentations, hands-on workshops, interaction via Audience Response System (ARS) and poster presentations over 3.5 days at the Keystone Conference Center in Keystone, CO. The activity took place on February 3-6, 2016. Accreditation Details: This program was certified for 14.75 AMA PRA Category 1 Credits and 15 Nursing Contact Hours. National Quality Strategy Priorities: Making Care Safer, Treatment and Prevention

Executive Summary Outcomes and Learning Objectives Educational Outcomes Strategy: National Jewish Health measured knowledge, competence and self-reported performance for this activity. The success of the program was measured by the following: Pre-test Post-test Evaluation 45-day Follow-Up Survey Learning Objectives Relating to Asthma and COPD Discuss techniques for optimizing asthma pharmacotherapy, including adherence. Summarize the role of biomarkers and phenotypes in asthma. Recognize an asthma/copd overlap and list appropriate treatments. Discuss the 2014 GOLD guidelines and their application to diagnosis and management of COPD. Discuss recent clinical data related to COPD patients and implications for clinical practice.

Level 1 Outcomes - Participation (n=130) Nurse Nurse Practitioner Other 13 17 Physician Assistant 10 18 72 Physician On average, attendees treat 6 patients per week with conditions discussed during the conference. On average, participants have been in practice for 14 years. Other: BA, BS, CCRC, CCRP, MBA, MS, MA, MSPH, RD, PhD, PT

Level 1 Outcomes Participation - Specialties (n=130) Other Pediatrics Family Medicine 16 20 10 Internal Medicine 7 37 Allergy 40 3 Pulmonary OTHER: Critical Care Emergency Immunotherapy Informatics Interven. Pulm Pathology Pharmaceutical Pharmacy Physiology Rehab Research Respiratory

Level 2 and 3 Outcomes Satisfaction and Learning Analysis of Participants Responses Related to Learning Objectives and Educational Needs How well did the activity improve your ability to treat or manage your patients? 7 35 58 How well did the conference enhance your ability to apply the learning objectives to your practice? 6 39 55 How well did the information presented reinforce and/or improve your current skills? 5 34 61 How well did the activity meet your educational needs? 3 40 57 0 10 20 30 40 50 60 70 Measured in % Fair Good Excellent

Level 3 and 4 Outcomes: Learning (Knowledge and Competence) Level 3 and 4 outcomes were measured by comparing participants pre- and post-test answers. The attendees responses to these questions demonstrated that participants gained knowledge as a result of the activity. The overall average increase in correct responses from pre- to post-activity was 33%. 70% 60% 50% 40% 30% 20% 45% 60% Knowledge gain was marked by an increase in correct responses from pre- to post-activity, as well as 94% indicating learning objectives were met. 10% 0% Pre-Test Post-Test Measured in % of Correct Answers

Pre/Post Test Comparison: Indication of Knowledge Gained Question Example Addressing Asthma/COPD Learning Objectives Question: Which of the following is appropriate initial therapy for a patient with ACOS? Measured in % 90 80 70 60 50 40 30 20 10 0 9 1 16 14 IL5 receptor antagonistlong-acting muscarinic antagonist monotherapy Pre-Test 10 5 Long-acting betaagonist monotherapy Post-Test 65 80 Inhaled corticosteroid Answer: The correct answer is d. Inhaled corticosteroid with or without a long-acting bronchodilator. Only 65% of participants that responded selected the correct answer during the pre-test, compared to 80% in the post-test, demonstrating a 23% increase in declarative and procedural knowledge and competence.

Pre/Post Test Comparison: Indication of Knowledge Gained Question Example Addressing Asthma Learning Objectives Question: The most common phenotype in asthma is: Measured in % 90 80 70 60 50 40 30 20 10 0 10 13 69 80 5 5 0 0 Neutrophilic Eosinophilic Pauciimmune Monocytic phenotype 12 6 None of the above Pre-Test Post-Test Answer: The correct answer is b. Eosinophilic. Only 69% of participants that responded selected the correct answer during the pre-test, compared to 80% in the post-test, demonstrating a 16% increase in declarative and procedural knowledge and competence.

Pre/Post Test Comparison: Indication of Knowledge Gained Question Example Addressing Asthma Learning Objectives Question: Which of the following is an IL-13 induced protein which predicts better response to inhaled corticosteroids and Anti-IL13? 60 54 50 40 30 40 30 30 Measured in % 20 10 0 Circulating eosinophil levels 11 6 Circulating neutrophil levels 6 1 14 Periostin Epx Sputum neutrophils 6 Pre-Test Post-Test Answer: The correct answer is c. Periostin. Only 30% of participants that responded selected the correct answer during the pre-test, compared to 54% in the post-test, demonstrating a 80% increase in declarative and procedural knowledge and competence.

Pre/Post Test Comparison: Indication of Knowledge Gained Question Example Addressing Asthma/COPD Learning Objectives Question: Which of the following is diagnostic of ACOS? 120 100 80 75 96 60 Measured in % 40 20 0 4 Eosinophilia 17 0 2 No response of FEV1 (forced expired volume in one second) to inhaled short-acting beta-agonist Features of both asthma and COPD 5 2 Normal spirometry without airflow limitation Pre-Test Post-Test Answer: The correct answer is c. Features of both asthma and COPD. Only 75% of participants that responded selected the correct answer during the pre-test, compared to 96% in the post-test, demonstrating a 28% increase in declarative and procedural knowledge and competence.

Level 4 Outcomes Competence (Intent to Change) 90% of participants stated that they are somewhat to extremely likely to make a change to their practice based on the content presented. The changes I intend to make in my practice include: 70 62.7% 65.1% 60 Measured in % of Respondents 50 40 30 27.7% 33.7% Other includes: Increased awareness of complex treatments More referrals 20 10 4.8% 0 Change my screening/prevention practice Incorporate different diagnostic strategies into patient evaluation Use alternative communication methodologies with patients and families Modify treatment plans Other (please specify) N = 83

80 70 60 50 40 30 20 10 Level 5 Outcomes Self-reported Performance 45 days after the conference, participants indicated the following changes were incorporated into their practice: 20% 67.5% 37.5% 62.5% 12.5% Measured in % of Respondents Other includes: Biomarker insight and consensus GERD information 0 Change my screening/prevention practice Incorporate different diagnostic strategies into patient evaluation Use alternative communication methodologies with patients and families Modify treatment plans Other (please specify) N = 41

Level 5 Outcomes Self-reported Performance An important predictor in this interactive activity for competence and self-reported performance change comes from our 45-day post-activity assessment: 95% of our participants (n=41) stated that this activity provided new ideas or information that they have used in practice.

From Classroom to Practice Based on the educational content delivered at the Pulmonary and Allergy Update, participants have changed their screening and prevention practices, have incorporated different diagnostic strategies into patient evaluation, have modified treatment plans and are using alternative communication methods with their pulmonary and allergy patients and their families as they indicated at the meeting. The Pulmonary and Allergy Update fulfills National Quality Strategy Priorities in making care safer for patients with asthma, COPD, atopic dermatitis and other pulmonary and allergy conditions, as well as promoting the most effective treatment and prevention practices for these disease states.

Interactivity Audience Response System (ARS) technology was used throughout the Pulmonary and Allergy Update to engage the audience, promote discussion, and enhance interactivity. This was our second year in utilizing this technology for response and reflection. Some attendees provided their feedback regarding how ARS enhanced their learning experience. Here are a few examples: As an adult learning tactic, I like to use the ARS system Seeing how my response compared with the group is good feedback ARS did lead to discussion. For example, the I Don't Know" response made me feel like I was lacking basic knowledge. Yet, I realized after the discussion that modern medicine doesn't know the answer. Faculty presenters were able to address knowledge gaps instantly as a result of incorporating ARS into presentations.

Overall Activity Impact Main Findings: The attendees (n=83) responses to post-test evaluation questions demonstrated the following: 100% of participants indicated that the materials were presented objectively and free of commercial bias. 95% of participants indicated that the activity addressed strategies for overcoming barriers to optimal patient care. 100% of participants stated that the content presented was evidence-based and clinically relevant.

Overall Activity Impact Continued Main Findings: The attendees (n=41) responses to a follow-up survey 45 days after the program demonstrated the following: Attendees report that an average of 9 of their patients have already benefited form the information learned during this CME activity. Attendees report they need more education in the following area: o Optimizing asthma pharmacotherapy o Smoking cessation strategies o Allergen immunotherapy o Weight loss management o Pulmonary hypertension o Sarcoidosis o Chronic sinusitis o COPD treatment and management o Vocal cord dysfunction treatment/diagnosis o Reading chest CT scans o Role of biomarkers and phenotypes in asthma o Contact dermatitis o Recognizing the asthma/copd overlap o Eosinophilic esophagitis o Treatments for atopic dermatitis

Critical Learning Points Identified by Participants We can better help asthmatics if we figure out specific type of asthma people have. There's lots of new treatment options. Important information on the new medications for asthma. How to better use biologics. I learned the most about biomarkers in asthma. It was good to learn about what biomarkers we may be able to use in the future to better individualize a patient s treatment. Now I understand much more about atopic dermatitis. I will change the way I treat my COPD patients, particularly the way I recommend inhaled medications. Maintain a broader differential diagnosis for many of the patients and conditions that present in my office. The new category of ACOS and discussion of first line treatment. Asthma/COPD overlap is a difficult diagnosis to make and should be considered very carefully before drawing conclusions. Better awareness immune deficiency presenting as an allergic disease and the importance nonacid GERD acid in asthma control. To consider immune deficiency in allergic patients.

Participant Comments Nice job - conference has an excellent reputation. Excellent lectures. I enjoyed and learned new things. Thank you for hosting the conference. National Jewish sounds like a very nice place to be treated, especially since so many resources are available. Excellent conference - looking forward to next year! Wonderful conference! Excellent faculty and ability to ask questions outside of the conference time. Conference overall exceeded my expectations. Wonderful speakers. Excellent support staff. One of the best conferences for me with excellent material presented that is practical but still new and stimulating. Refreshing knowledge of practical medicine.